The Alliance for BioTherapeutics was formed in 2007 due to the difficulties patients faced receiving intravenous immune globulin (IVIG) therapy. It received its 501(c)(3) status in 2009 and became the first national organization to represent all patients and providers of plasma therapies. In March 2011, The Alliance changed its name to The Alliance For BioTherapeutics to be the leading voice for all who benefit from biotherapeutics. Through our joint efforts and affiliations, we aspire to ensure that all individuals in need receive access to and adequate reimbursement for life-saving and life-enhancing biotherapeutics.

The Alliance helps patients who lack access to lifesaving therapies, have reimbursement restrictions and/or are denied coverage. We also help patients who can no longer afford therapies prescribed by their physicians because of new policy restrictions.

In order to fully understand how the Alliance impacts people’s lives, it is important to understand the communities it helps. We are directly involved with aiding individuals who suffer from autoimmune, cancer, hemophilia and bleeding disorders, neuropathy, primary immunodeficiency diseases, and other rare, chronic, and/or genetic disorders.

Compassion: We reach out with open hearts, gentle spirits, and genuine concern for patients, families and care givers affected by chronic, rare and genetic disorders that rely on biotherapeutics to improve the quality of peoples’ lives.
                                                                                                 
Support: We stand by one another through good times and bad to ensure that NO patient ever feels alone.

Community: We embrace all members of the community including:  patient organizations, healthcare providers, corporate leaders, payers, and government leaders to work together to ensure that patients in need of biotherapeutics have access to these live-saving therapies without coinsurance/specialty tier plans hampering access to the therapies that can save the lives of these individuals.

Abbie Cornett, President and Chair
         Nebraska State Senator

Roger Kobayashi, MD, Secretary
         Clinical Professor, UCLA School of Medicine and Senior
         Partner of Allergy, Asthma & Immunology Associates

Bob Goldberg, Treasurer
         Executive Director, The Myositis Association

Mary Alexander, RN, CRNI®, CAE, FAAN
         Chief Executive Officer, Infusion Nurses Society

Lisa Christopher-Stine, MD
         Co-Director, Johns Hopkins Myositis Center
         Assistant Professor of Medicine, Johns Hopkins University
         School of Medicine

Neil Herson
         President, ASD Healthcare

Todd Levine, MD
         Co-Director of Peripheral Neuropathy Clinic
         Banner Good Samaritan Medical Center
         Clinical Assistant Professor, University of Arizona

Flemming Nielsen,
         President, Octapharma USA

Patrick Schmidt,
         Chief Executive Officer, FFF Enterprises

Dominick Spatafora
         President, Neuropathy Action Foundation

Tina Tockarshewsky
         President and Chief Executive Officer, The Neuropathy Association